U.S. patent application number 11/377470 was filed with the patent office on 2006-08-24 for hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- -2, 4-dione maleic acid salt.
This patent application is currently assigned to SmithKline Beecham p.l.c.. Invention is credited to Paul David James Blackler, David C. Lee, Michael John Sasse.
Application Number | 20060189659 11/377470 |
Document ID | / |
Family ID | 10823694 |
Filed Date | 2006-08-24 |
United States Patent
Application |
20060189659 |
Kind Code |
A1 |
Sasse; Michael John ; et
al. |
August 24, 2006 |
Hydrate of
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-
-2, 4-dione maleic acid salt
Abstract
A hydrate of
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione-
, maleic acid salt, characterised in that it: (i) comprises water
in the range of from 0.2 to 1.1% w/w ; and (ii) provides an infra
red spectrum containing peaks at 764 and 579 cm.sup.-1; and/or
(iii) provides an X-ray powder diffraction (XRPD) pattern
substantially as set out in Figure II; a process for the
preparation of such a compound, a pharmaceutical composition
containing such a compound and the use of such a compound or
composition in medicine.
Inventors: |
Sasse; Michael John;
(Tunbridge Wells, GB) ; Blackler; Paul David James;
(Tonbridge, GB) ; Lee; David C.; (Cambridgeshire,
GB) |
Correspondence
Address: |
GLAXOSMITHKLINE;Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia
PA
19406-0939
US
|
Assignee: |
SmithKline Beecham p.l.c.
|
Family ID: |
10823694 |
Appl. No.: |
11/377470 |
Filed: |
March 16, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10692544 |
Oct 24, 2003 |
7045633 |
|
|
11377470 |
Mar 16, 2006 |
|
|
|
10072096 |
Feb 7, 2002 |
6664278 |
|
|
10692544 |
Oct 24, 2003 |
|
|
|
09581719 |
Jun 16, 2000 |
|
|
|
PCT/EP98/08154 |
Dec 14, 1998 |
|
|
|
10072096 |
Feb 7, 2002 |
|
|
|
Current U.S.
Class: |
514/340 ;
546/269.7 |
Current CPC
Class: |
A61P 3/10 20180101; C07D
417/12 20130101; A61P 3/00 20180101 |
Class at
Publication: |
514/340 ;
546/269.7 |
International
Class: |
A61K 31/4439 20060101
A61K031/4439; C07D 417/02 20060101 C07D417/02 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 16, 1997 |
GB |
GB9726568.0 |
Claims
1. A hydrate of
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione-
, maleic acid salt, characterised in that it: (i) comprises water
in the range of from 0.2 to 1.1% w/w; and (ii) provides an infra
red spectrum containing peaks at 764 and 579 cm.sup.-1; and/or
(iii) provides an X-ray powder diffraction (XRPD) pattern
substantially as set out in Figure II.
2. A hydrate according to claim 1, wherein the water content is in
the range of from 05 to 0.6% w/w.
3. A hydrate according to claim 1, which provides an infra red
spectrum substantially in accordance with Figure I.
4. A hydrate according to claim 1, which provides an X-ray powder
diffraction (XRPD) pattern substantially as set out in Figure
II.
5. A hydrate according to claim 1, in isolated form.
6. A hydrate according to claim 1, in pure form.
7. A hydrate according to claim 1, in crystalline form.
8. A compound in the form of a rehydratable form of a hydrate
according to claim 1.
9. A process for preparing a hydrate according to claim 1,
characterized in that
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2-
,4-dione, maleic acid salt is crystallised from aqueous
ethanol.
10. A process according to claim 11, wherein the aqueous ethanol
contains from 2% to 2.5% of water by volume.
11. A pharmaceutical composition comprising an effective, non-toxic
amount of a hydrate according to claim 1 and a pharmaceutically
acceptable carrier therefor.
12. A hydrate according to claim 1, for use as an active
therapeutic substance.
13. A hydrate according to claim 1, for use in the treatment and/or
prophylaxis of diabetes mellitus, conditions associated with
diabetes mellitus and certain complications thereof.
14. A method for the treatment and/or prophylaxis of diabetes
mellitus, conditions associated with diabetes mellitus and certain
complications thereof, in a human or non-human mammal which
comprises administering an effective, non-toxic, amount of Hydrate
to a human or non-human mammal in need thereof.
Description
[0001] This application is a continuation of application Ser. No.
10/692,544, filed Oct. 24, 2003, which is a continuation of
application Ser. No. 10/072,096, filed Feb. 7, 2002 (now U.S. Pat.
No. 6,664,278), which is a continuation of application Ser. No.
09/581,719, filed Jun. 16, 2000 (abandoned), which is a 371 of
International Application No. PCT/EP98/08154, filed Dec. 14, 1998,
which claims benefit of Great Britain Application No. 9726568.0,
filed Dec. 16, 1997.
BACKGROUND OF THE INVENTION
[0002] This invention relates to a novel pharmaceutical, to a
process for the preparation of the pharmaceutical and to the use of
the pharmaceutical in medicine.
[0003] International Patent Application, Publication Number
WO94/05659 discloses certain thiazolidinedione derivatives having
hypoglycaemic and hypolipidaemic activity including
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione-
, maleic acid salt (hereinafter also referred to as "Compound
(I)").
[0004] Compound (I) is disclosed solely as an anhydrous form. It
has now been discovered that Compound (I) exists in a novel
hydrated form which is particularly suitable for bulk preparation
and handling. This can be prepared by an efficient, economic and
reproducible process particularly suited to large scale
preparation.
[0005] The novel hydrate also has useful pharmaceutical properties
and in particular it is indicated to be useful for the treatment
and/or prophylaxis of diabetes mellitus, conditions associated with
diabetes mellitus and certain complications thereof.
SUMMARY OF THE INVENTION
[0006] Accordingly, the present invention provides a hydrate of
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione-
, maleic acid salt (the "Hydrate") characterised in that the
Hydrate: [0007] (i) comprises water in the range of from 0.2 to
1.1% w/w ; and [0008] (ii) provides an infra red spectrum
containing peaks at 764 and 579 cm.sup.-1; and/or [0009] (iii)
provides an X-ray powder diffraction (XRPD) pattern substantially
as set out in Figure II.
[0010] Suitably, the water content of the Hydrate is in the range
of from 0.4 to 0.9% w/w, especially 0.5 to 0.6% w/w, for example
0.54% w/w or 0.6% w/w.
[0011] In one favoured aspect, the Hydrate provides an infra red
spectrum substantially as set out in accordance with Figure I.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1 is the infrared spectrum of the Hydrate.
[0013] FIG. 2 is the X-ray powder diffraction pattern of the
Hydrate.
DETAILED DESCRIPTION OF THE INVENTION
[0014] The Hydrate can exist in certain dehydrated forms which
reversibly convert to the Hydrate when contacted with water, either
in liquid or vapour form. The present invention encompasses all
such reversibly rehydratable forms of the Hydrate.
[0015] The present invention encompasses the Hydrate isolated in
pure form or when admixed with other materials, for example the
known anhydrous form of Compound I, the above mentioned reversibly
rehydratable forms or any other material.
[0016] Thus in one aspect there is provided the Hydrate in isolated
form.
[0017] In a further aspect there is provided the Hydrate in pure
form.
[0018] In yet a further aspect there is provided the Hydrate in
crystalline form.
[0019] The invention also provides a process for preparing the
Hydrate, characterised in that
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione-
, maleic acid salt is crystallised from an aqueous alkanolic
solvent, preferably containing from 2.0 to 2.5% by volume of water,
most preferably 2.0 to 2.3%, for example 2.1% by volume of
water.
[0020] Suitable aqueous alkanolic solvents include aqueous ethanol,
typically aqueous denatured ethanol, and aqueous isopropanol, or
mixtures thereof.
[0021] Crystallisation and any recrystallisation is generally
carried out at low to ambient temperature, such as in the range of
between 0 to 30.degree. C. for example 25.degree. C.; alternatively
crystallisation may be initiated at an elevated temperature, such
as in the range of between 30.degree. C. and 60.degree. C. for
example 35.degree. C., and then completed by allowing the
temperature of the solvent to cool to ambient or low temperature,
such as in the range of between 0 to 30.degree. C. for example
25.degree. C.
[0022] The crystallisation can be initiated by seeding with
crystals of the Hydrate but this is not essential.
[0023] Compound I is prepared according to known procedures, such
as those disclosed in WO94/05659. The disclosures of WO94/05659 are
incorporated herein by reference.
[0024] When used herein the term `prophylaxis of conditions
associated with diabetes mellitus` includes the treatment of
conditions such as insulin resistance, impaired glucose tolerance,
hyperinsulinaemia and gestational diabetes.
[0025] Diabetes mellitus preferably means Type II diabetes
mellitus.
[0026] Conditions associated with diabetes include hyperglycaemia
and insulin resistance, especially acquired insulin resistance and
obesity. Further conditions associated with diabetes include
hypertension, cardiovascular disease, especially atherosclerosis,
certain eating disorders, in particular the regulation of appetite
and food intake in subjects suffering from disorders associated
with under-eating, such as anorexia nervosa, and disorders
associated with over-eating, such as obesity and anorexia bulimia.
Additional conditions associated with diabetes include polycystic
ovarian syndrome and steroid induced insulin resistance.
[0027] The complications of conditions associated with diabetes
mellitus encompassed herein includes renal disease, especially
renal disease associated with the development of Type II diabetes
including diabetic nephropathy, glomerulonephritis, glomerular
sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end
stage renal disease.
[0028] As used herein `aqueous` with reference to a given solvent
or solvent mixture refers to a solvent which contains sufficient
water to provide Hydrate i.e having from 0.2 to 1.1% w/w of
water.
[0029] As mentioned above the compound of the invention has useful
therapeutic properties: The present invention accordingly the
Hydrate for use as an active therapeutic substance.
[0030] More particularly, the present invention provides the
Hydrate for use in the treatment and/or prophylaxis of diabetes
mellitus, conditions associated with diabetes mellitus and certain
complications thereof.
[0031] The Hydrate may be administered per se or, preferably, as a
pharmaceutical composition also comprising a pharmaceutically
acceptable carrier. The formulation of the Hydrate and dosages
thereof are generally as disclosed for Compound (I) in
International Patent Application, Publication Number
WO94/05659.
[0032] Accordingly, the present invention also provides a
pharmaceutical composition comprising the Hydrate and a
pharmaceutically acceptable carrier therefor.
[0033] The Hydrate is normally administered in unit dosage
form.
[0034] The active compound may be administered by any suitable
route but usually by the oral or parenteral routes. For such use,
the compound will normally be employed in the form of a
pharmaceutical composition in association with a pharmaceutical
carrier, diluent and/or excipient, although the exact form of the
composition will naturally depend on the mode of
administration.
[0035] Compositions are prepared by admixture and are suitably
adapted for oral, parenteral or topical administration, and as such
may be in the form of tablets, capsules, oral liquid preparations,
powders, granules, lozenges, pastilles, reconstitutable powders,
injectable and infusable solutions or suspensions, suppositories
and transdermal devices. Orally administrable compositions are
preferred, in particular shaped oral compositions, since they are
more convenient for general use.
[0036] Tablets and capsules for oral administration are usually
presented in a unit dose, and contain conventional excipients such
as binding agents, fillers, diluents, tabletting agents,
lubricants, disintegrants, colourants, flavourings, and wetting
agents. The tablets may be coated according to well known methods
in the art.
[0037] Suitable fillers for use include cellulose, mannitol,
lactose and other similar agents. Suitable disintegrants include
starch, polyvinylpyrrolidone and starch derivatives such as sodium
starch glycollate. Suitable lubricants include, for example,
magnesium stearate. Suitable pharmaceutically acceptable wetting
agents include sodium lauryl sulphate.
[0038] Solid oral compositions may be prepared by conventional
methods of blending, filling, tabletting or the like. Repeated
blending operations may be used to distribute the active agent
throughout those compositions employing large quantities of
fillers. Such operations are, of course, conventional in the
art.
[0039] Oral liquid preparations may be in the form of, for example,
aqueous or oily suspensions, solutions, emulsions, syrups, or
elixirs, or may be presented as a dry product for reconstitution
with water or other suitable vehicle before use. Such liquid
preparations may contain conventional additives such as suspending
agents, for example sorbitol, syrup, methyl cellulose, gelatin,
hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate
gel or hydrogenated edible fats, emulsifying agents, for example
lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles
(which may include edible oils), for example, almond oil,
fractionated coconut oil, oily esters such as esters of glycerine,
propylene glycol, or ethyl alcohol; preservatives, for example
methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired
conventional flavouring or colouring agents.
[0040] For parenteral administration, fluid unit dose forms are
prepared containing a compound of the present invention and a
sterile vehicle. The compound, depending on the vehicle and the
concentration, can be either suspended or dissolved. Parenteral
solutions are normally prepared by dissolving the active compound
in a vehicle and filter sterilising before filling into a suitable
vial or ampoule and sealing. Advantageously, adjuvants such as a
local anaesthetic, preservatives and buffering agents are also
dissolved in the vehicle. To enhance the stability, the composition
can be frozen after filling into the vial and the water removed
under vacuum.
[0041] Parenteral suspensions are prepared in substantially the
same manner except that the active compound is suspended in the
vehicle instead of being dissolved and sterilised by exposure to
ethylene oxide before suspending in the sterile vehicle.
Advantageously, a surfactant or wetting agent is included in the
composition to facilitate uniform distribution of the active
compound.
[0042] In addition such compositions may contain further active
agents such as anti-hypertensive agents and diuretics.
[0043] As is common practice, the compositions will usually be
accompanied by written or printed directions for use in the medical
treatment concerned.
[0044] As used herein the term `pharmaceutically acceptable`
embraces compounds, compositions and ingredients for both human and
veterinary use: for example the term `pharmaceutically acceptable
salt` embraces a veterinarily acceptable salt.
[0045] The present invention further provides a method for the
treatment and/or prophylaxis of diabetes mellitus, conditions
associated with diabetes mellitus and certain complications
thereof, in a human or non-human mammal which comprises
administering an effective, non-toxic, amount of Hydrate to a human
or non-human mammal in need thereof.
[0046] Conveniently, the active ingredient may be administered as a
pharmaceutical composition hereinbefore defined, and this forms a
particular aspect of the present invention.
[0047] In the treatment and/or prophylaxis of diabetes mellitus,
conditions associated with diabetes mellitus and certain
complications thereof Hydrate may be taken in doses, such as those
described above.
[0048] Similar dosage regimens are suitable for the treatment
and/or prophylaxis of non-human mammals.
[0049] In a further aspect the present invention provides the use
of Hydrate for the manufacture of a medicament for the treatment
and/or prophylaxis of diabetes mellitus, conditions associated with
diabetes mellitus and certain complications thereof.
[0050] No adverse toxicological effects are indicated for the
compounds of the invention in the above mentioned treatments.
[0051] The following examples illustrate the invention but do not
limit it in any way.
EXAMPLE 1
Preparation of hydrate of
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione-
, maleic acid salt
[0052]
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,-
4-dione free base (4.0 g) and maleic acid (1.40 g, 1.05 molar
equivalents) were heated in denatured ethanol (40 ml) containing
additional water (0.51 g, i.e. a total water content of
approximately 2.1% (v/v)) to 60.degree. C. and held at this
temperature for 30 minutes during which time a solution was
obtained. The solution was filtered, re-heated to 50.degree. C.,
and then cooled with stirring at a rate of 1 deg/min, resulting in
crystallisation at 35.degree. C. The resulting suspension was
cooled to 25.degree. C. and stirred for two hours. The product was
filtered, washed with 99% denatured ethanol (8 ml) and dried at
50.degree. C. in vacuo for 24 hours to give the title compound
(4.38 g, 82%). The water content of the product was 0.54% w/w.
[0053] CHARACTERISING DATA: The following characterising data was
generated for the Hydrate:
A Infrared
[0054] The infrared absorption spectrum of a mineral oil dispersion
of the Hydrate was obtained using a Nicolet 710 FT-IR spectrometer
at 2 cm.sup.-1 resolution. Data were digitised at 1 cm.sup.-1
interval. The spectrum obtained is shown in Figure I. Peak
positions are as follows: 3129, 2776, 1756, 1747, 1706, 1641, 1617,
1586, 1542, 1512, 1413, 1351, 1331, 1290, 1264, 1246, 1210, 1182,
1163, 1108, 1078, 1064, 1031, 1005, 975, 955, 926, 865, 764, 738,
719, 662, 619, 579, 557, 532, 525, and 508 cm.sup.-1.
B X-Ray Powder Diffraction (XRPD)
[0055] The XRPD pattern of the Hydrate is shown below in Figure II
and a summary of the XRPD angles and calculated lattice spacing
characteristic of the Hydrate is given in Table I. A PW1710 X-ray
powder diffractometer (Cu X-ray source) was used to generate the
spectrum using the following acquisition conditions: TABLE-US-00001
Tube anode: Cu Generator tension: 40 kV Generator current: 30 mA
Start angle: 3.5 .degree.2.theta. End angle: 35.0 .degree.2.theta.
Step size: 0.020 Time per step: 4.550 s
[0056] TABLE-US-00002 TABLE I X-Ray Powder Diffraction Angles and
Calculated Lattice Spacing Characteristic of the Hydrate.
Diffraction Angle Lattice Spacing (.degree.2.theta.) (Angstroms)
7.6 11.65 8.9 9.90 9.7 9.09 15.1 5.85 15.6 5.68 17.0 5.22 17.5 5.08
17.9 4.96 19.2 4.62 20.1 4.41 20.6 4.30 22.2 4.00 23.8 3.73 24.4
3.64 25.2 3.54 25.9 3.44 26.7 3.34 27.5 3.25 28.0 3.19 29.9 2.99
31.5 2.84
* * * * *